论文部分内容阅读
帕金森氏病(PD)是发生于中、老年期常见的中枢神经系统变性疾病,由于黑质多巴胺(DA)能神经元丢失变性,纹状体DA递质显著降低,导致震颤、肌强直、行动缓慢和姿势反射障碍等临床症状。本世纪60年代,用于DA替代疗法的左旋多巴的问世,开辟了PD治疗的新纪元。随着对本病治疗研究的不断深入,外周多巴脱羧酶抑制剂(DDC-Ⅰ)与左旋多巴组成复方多巴、平胺氧化酶B抑制剂(MAOBI)、DA受体激动剂、促DA释放剂、儿茶酚-氧位-甲基转移酶抑制剂(COMTI)相断问世。此外,还研制成功了一种药物多种剂型(如标准片和控释片美多巴或帕金宁)。上述药物对PD的治疗显示了十分有效的作用,在很大程度上可使该病患者提高工作效率和改善生活质量。
Parkinson’s disease (PD) is a common central nervous system degenerative disease that occurs in middle and old age. Due to the degeneration of dopaminergic neurons in the substantia nigra, striatal DA neurotransmitters are significantly reduced, resulting in tremor, myotonia, Slow motion and postural reflex disorders and other clinical symptoms. The 1960s, the advent of levodopa for DA replacement therapy, opened up a new era of PD treatment. With the deepening of the treatment of this disease, peripheral dopaminergic decarboxylase inhibitors (DDC-Ⅰ) and levodopa composition of dopa, MA BMI (MAOBI), DA receptor agonist, promote DA release agent, catechol-O-methyltransferase inhibitor (COMTI) phase out. In addition, a variety of dosage forms (such as standard tablets and controlled release tablets of metopar or parkin) have also been developed. The above drugs show a very effective effect on the treatment of PD, to a large extent, enable the patients to work more efficiently and improve their quality of life.